5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation

被引：49

作者：

Bolanos-Meade, Javier ^{[1
]}

Smith, B. Douglas

Gore, Steven D.

McDevitt, Michael A.

Luznik, Leo

Fuchs, Ephraim J.

Jones, Richard J.

机构：

[1] Sidney Kimmel Comprehens Canc Ctr johns Hopkins, George W Santos Bone Marrow Transplant Serv, Dept Oncol, Baltimore, MD 21231 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 05期

关键词：

Acute myeloid leukemia; Donor lymphocyte infusion; 5-Azacytidine; Myelodysplastic syndrome; Graft-versus-host disease; STEM-CELL TRANSPLANTATION; DONOR LYMPHOCYTE INFUSIONS; CONVENTIONAL CARE REGIMENS; VERSUS-HOST-DISEASE; CLASS-I ANTIGENS; MYELODYSPLASTIC SYNDROME; ACUTE-LEUKEMIA; UP-REGULATION; AZACITIDINE; 5-AZA-2'-DEOXYCYTIDINE;

D O I：

10.1016/j.bbmt.2010.10.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Relapse after allogeneic blood or marrow transplantation carries a very poor prognosis. Current strategies for management that include donor lymphocyte infusions (DLIs) and salvage chemotherapies are usually toxic and ineffective. Here we report the outcome of 10 patients with myeloid malignancies that received 5-azacytidine after a failed allogeneic bone marrow transplant. Of the 10 patients, 6 achieved a complete remission, 1 had stable disease, and 3 progressed after a median of 6 cycles administered. Only 1 patient has died (of disease progression), and no flares of graft-versus-host disease (GVHD) were observed with 5-azacytidine. As of latest follow-up, the median overall survival (OS) for the group was 422.5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted. Biol Blood Marrow Transplant 17: 754-758 (2011) (C) 2011 American Society for Blood and Marrow Transplantation

引用

页码：754 / 758

页数：5

共 30 条

[1] The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
Almstedt, Maika
Blagitko-Dorfs, Nadja
Duque-Afonso, Jesus
Karbach, Julia
Pfeifer, Dietmar
Jaeger, Elke
Luebbert, Michael
[J]. LEUKEMIA RESEARCH, 2010, 34 (07) : 899 - 905
[2] Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen
Bolanos-Meade, J.
Luznik, L.
Muth, M.
Matsui, W. H.
Huff, C. A.
Smith, B. D.
Levy, M. Y.
Kasamon, Y. L.
Swinnen, L. J.
Powell, J. D.
Brodsky, R. A.
Ambinder, R. F.
Jones, R. J.
Fuchs, E. J.
[J]. BONE MARROW TRANSPLANTATION, 2009, 43 (06) : 477 - 480
[3] In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Choi, Jaebok
Ritchey, Julie
Prior, Julie L.
Holt, Matthew
Shannon, William D.
Deych, Elena
Piwnica-Worms, David R.
DiPersio, John F.
[J]. BLOOD, 2010, 116 (01) : 129 - 139
[4] Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR)
Coral, S
Sigalotti, L
Gasparollo, A
Cattarossi, I
Visintin, A
Cattelan, A
Altomonte, M
Maio, M
[J]. JOURNAL OF IMMUNOTHERAPY, 1999, 22 (01): : 16 - 24
[5] Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine
Daurkin, Irina
Eruslanov, Evgeniy
Vieweg, Johannes
Kusmartsev, Sergei
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (05) : 697 - 706
[6] Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
Fandy, Tamer E.
Herman, James G.
Kerns, Patrick
Jiemjit, Anchalee
Sugar, Elizabeth A.
Choi, Si-Ho
Yang, Allen S.
Aucott, Timothy
Dauses, Tianna
Odchimar-Reissig, Rosalie
Licht, Jonathan
McConnell, Melanie J.
Nasrallah, Chris
Kim, Marianne K. H.
Zhang, Weijia
Sun, Yezou
Murgo, Anthony
Espinoza-Delgado, Igor
Oteiza, Katharine
Owoeye, Ibitayo
Silverman, Lewis R.
Gore, Steven D.
Carraway, Hetty E.
[J]. BLOOD, 2009, 114 (13) : 2764 - 2773
[7] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Fenaux, Pierre
Mufti, Ghulam J.
Hellstrom-Lindberg, Eva
Santini, Valeria
Gattermann, Norbert
Germing, Ulrich
Sanz, Guillermo
List, Alan F.
Gore, Steven
Seymour, John F.
Dombret, Herve
Backstrom, Jay
Zimmerman, Linda
McKenzie, David
Beach, C. L.
Silverman, Lewis R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) : 562 - 569
[8] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Fenaux, Pierre
Mufti, Ghulam J.
Hellstrom-Lindberg, Eva
Santini, Valeria
Finelli, Carlo
Giagounidis, Aristoteles
Schoch, Robert
Gattermann, Norbert
Sanz, Guillermo
List, Alan
Gore, Steven D.
Seymour, John F.
Bennett, John M.
Byrd, John
Backstrom, Jay
Zimmerman, Linda
McKenzie, David
Beach, C. L.
Silverman, Lewis R.
[J]. LANCET ONCOLOGY, 2009, 10 (03) : 223 - 232
[9] 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
Field, T.
Perkins, J.
Huang, Y.
Kharfan-Dabaja, M. A.
Alsina, M.
Ayala, E.
Fernandez, H. F.
Janssen, W.
Lancet, J.
Perez, L.
Sullivan, D.
List, A.
Anasetti, C.
[J]. BONE MARROW TRANSPLANTATION, 2010, 45 (02) : 255 - 260
[10] Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma:: Immunotherapeutic implications
Fonsatti, Ester
Nicolay, Hugues J. M.
Sigalotti, Luca
Calabro, Luana
Pezzani, Laura
Colizzi, Francesca
Altomonte, Maresa
Guidoboni, Massimo
Marincola, Francesco M.
Maio, Michele
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (11) : 3333 - 3338

← 1 2 3 →